Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.

Jeeyun  Lee

Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences

Research Funding - AstraZeneca; Merck Sharp & Dohme

Ardaman  Shergill

Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago

Consulting or Advisory Role - Catalyst Pharmaceuticals; KLJ Associates; Pfizer; Triptych Health Partners

Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); TP Therapeutics (Inst); verastem (Inst)

Haeseong  Park

Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)

Keun-Wook  Lee

Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma

Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)

Hendrik-Tobias  Arkenau

Employment - Ellipses Pharma

Stock and Other Ownership Interests  - Ellipses Pharma

Consulting or Advisory Role - Bicycle Therapeutics; Daiichi Sankyo Pharmaceutical; Engitix; iOnctura; Labgenius; SERVIER

Yoon-Koo  Kang

Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks

Olugbenga Olanrele  Olowokure

No Relationships to Disclose

Jong Gwang  Kim

No Relationships to Disclose

Sung Yong  Oh

No Relationships to Disclose

Do-Youn  Oh

Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks

Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER

Dan  Costin

No Relationships to Disclose

Andrew William  Pippas

No Relationships to Disclose

Jen-Shi  Chen

Research Funding - Amgen; Astellas Pharma; AstraZeneca; Janssen; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; Senhwa Biosciences; TTY Biopharm

Marya F.  Chaney

Employment - Merck

Stock and Other Ownership Interests  - Merck

Travel, Accommodations, Expenses - Merck

Andrew  Koustenis

Employment - OncXerna Therapeutics; Verastem

Stock and Other Ownership Interests  - Lilly

Hagop  Youssoufian

No Relationships to Disclose

Lukas  Makris

Employment - Stathmi

Stock and Other Ownership Interests  - Atrin Pharmaceuticals (I); Cerus (I); Immunomic Therapeutics (I); Opsidio (I); Sana Biotechnology (I)

Kerry  Culm

Employment - Oncologie

Stock and Other Ownership Interests  - Bristol-Myers Squibb/Celgene

Patents, Royalties, Other Intellectual Property - Patent on administration of IMGN632 and IMGN779

Colleen M.  Mockbee

Employment - OncXerna Therapeutics

Leadership - OncXerna Therapeutics

Stock and Other Ownership Interests  - Iovance Biotherapeutics; Krystal Biotech; Mirati Therapeutics; Rocket Pharma; Sarepta Therapeutics

Consulting or Advisory Role - Elevation Oncology; Partner Therapeutics

Ian  Chau

Honoraria - Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics

Research Funding - Janssen-Cilag (Inst); Lilly (Inst)

Travel, Accommodations, Expenses - BMS; SERVIER